Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.32 |
| ▸ | CDK9 | P50750 | 4/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114991 | 1.00 | PIK3CD (0.39) | PIK3CDLRRK2OPRK1TLR8TLR7 | |
| SCHEMBL2113311 | 0.92 | TNF (0.35) | PIK3CDOPRK1PIK3R1 | |
| SCHEMBL2114025 | 0.87 | PIK3CD (0.38) | PIK3CDOPRK1TLR8TLR7TLR9 | |
| SCHEMBL2114702 | 0.87 | P2RX3 (0.38) | PIK3CDOPRK1P2RX3 | |
| SCHEMBL2114696 | 0.87 | P2RX3 (0.38) | PIK3CDOPRK1P2RX3 | |
| SCHEMBL2113554 | 0.86 | P2RX3 (0.35) | PIK3CDLRRK2OPRK1P2RX3PIK3R1 | |
| SCHEMBL2113556 | 0.86 | P2RX3 (0.35) | PIK3CDLRRK2OPRK1P2RX3PIK3R1 | |
| SCHEMBL2114085 | 0.86 | OPRK1 (0.34) | PIK3CDOPRK1CCNT1CDK9P2RX3 | |
| SCHEMBL2115342 | 0.86 | OPRK1 (0.38) | PIK3CDOPRK1CCNT1CDK9PIK3R1 | |
| SCHEMBL2115344 | 0.86 | OPRK1 (0.38) | PIK3CDOPRK1CCNT1CDK9PIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | claimed |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | PIK3CD 6/4885LRRK2 736/4885OPRK1 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.